Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ye, Wei Liang ^a   Zhao, Yi Pu ^a   Li, Huai Qiu ^a   Na, Ren ^a   Li, Fei ^a   Mei, Qi Bing ^a   Zhao, Ming Gao ^a   Zhou, Si Yuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC ANTIBIOTIC; BONE DENSITY CONSERVATION AGENT; DOXORUBICIN; MACROGOL DERIVATIVE; MICELLE;

ANIMAL; BONE NEOPLASMS; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG RELEASE; DRUG SCREENING; FEMALE; HUMAN; KINETICS; MICELLE; MICRO-COMPUTED TOMOGRAPHY; MOLECULARLY TARGETED THERAPY; MOUSE; NUCLEAR MAGNETIC RESONANCE; PARTICLE SIZE; PH; SECONDARY; TUMOR CELL LINE;

ALENDRONATE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG LIBERATION; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MICE; MICELLES; MOLECULAR TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARTICLE SIZE; POLYETHYLENE GLYCOLS; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942869612     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14614     Document Type: Article

References (66)

1. Mundy, G. R. Mechanisms of bone metastasis. Cancer 80 (Suppl 8), 1546 (1997).
2. Colleoni, M. et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 18(23), 3925 (2000).
3. Lipton, A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 37 (Suppl 2), S15 (2010).
4. Lipton, A. New strategies to prevent and manage bone complications in cancer. Clin Adv Hematol Oncol 9(1), 42 (2011).
5. Brubaker, K. D., Brown, L. G., Vessella, R. L., Corey, E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. Bmc Cancer 6, 15 (2006).
6. Shea, J. E., Miller, S. C. Skeletal function and structure: implications for tissue-targeted therapeutics. Adv Drug Deliv Rev 57(7), 945 (2005).
7. Chen, T. et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42(11), 1228 (2002).
8. Lin, J. H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18(2), 75 (1996).
9. Hochdorffer, K., Abu, Ajaj K., Schafer-Obodozie, C., Kratz, F. Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix. J Med Chem 55(17), 7502 (2012).
10. Pan, H. et al. Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymeralendronate conjugates. Mol Pharm 5(4), 548 (2008).
11. Wang, D. et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm 3(6), 717 (2006).
12. Uludag, H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 8(21), 1929 (2002).
13. Klenner, T. et al. Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J Cancer Res Clin Oncol 116(4), 341 (1990).
14. Ye, W. L. et al. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One 9(5), e97358 (2014).
15. Du, C. et al. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery. Biomaterials 34(12), 3087 (2013).
16. Andersson, L. et al. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates. Biomacromolecules 6(2), 914 (2005).
17. Kwon, G. S. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst 20(5), 357 (2003).
18. Kedar, U., Phutane, P., Shidhaye, S., Kadam, V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 6(6), 714 (2010).
19. Hengst, V., Oussoren, C., Kissel, T., Storm, G. Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331(2), 224 (2007).
20. Miller, K. et al. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 8(4), 1052 (2011).
21. Salerno, M. et al. Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 10(7), 649 (2010).
22. Pignatello, R., Sarpietro, M. G., Castelli, F. Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties. J Funct Biomater 3(1), 79 (2012).
23. Chen, H. et al. Alendronate-conjugated amphiphilic hyperbranched polymer based on Boltorn H40 and poly(ethylene glycol) for bone-targeted drug delivery. Bioconjug Chem 23(9), 1915 (2012).
24. Ye, W. L. et al. Synthesis of a new pH-sensitive folate-doxorubicin conjugate and its antitumor activity in vitro. J Pharm Sci 102(2), 530 (2013).
25. Miller, K. et al. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 48(16), 2949 (2009).
26. Lin, D. et al. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucinproducing, gastric-cancer cell line. J Biomed Nanotechnol 9(12), 2017 (2013).
27. Zhao, Z. et al. Biodegradable stereocomplex micelles based on dextran-block-polylactide as efficient drug deliveries. Langmuir 29(42), 13072 (2013).
28. Sawant, R. R., Torchilin, V. P. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 374(1-2), 114 (2009).
29. Shi, C. et al. Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. Biomaterials 35(30), 8711 (2014).
30. Molavi, O. et al. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy. Mol Pharm 7(2), 364 (2010).
31. Bansal, G. et al. Imparting mineral affinity to proteins with thiol-labile disulfide linkages. J Biomed Mater Res A 74(4), 618 (2005).
32. Doschak, M. R. et al. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol Pharm 6(2), 634 (2009).
33. Jakubowska, M. et al. Pulmonary metastases of the A549-derived lung adenocarcinoma tumors growing in nude mice. A multiple case study. Acta Biochim Pol 60(3), 323 (2013).
34. Nair, K. L., Jagadeeshan, S., Nair, S. A., Kumar, G. S. Folic acid conjugated delta-valerolactone-poly(ethylene glycol) based triblock copolymer as a promising carrier for targeted doxorubicin delivery. PLoS One 8(8), e70697 (2013).
35. Capeloa, T. et al. Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate. Neurotox Res 26(3), 216 (2014).
36. Akgun, B., Ates, D., Kaplan, M. Ganglioneuroblastoma of the thoracic spinal cord: a very rare case report. Acta Medica (Hradec Kralove) 55(1), 50 (2012).
37. Balas, F., Manzano, M., Horcajada, P., Vallet-Regi, M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 128(25), 8116 (2006).
38. Mai, Y., Eisenberg, A. Self-assembly of block copolymers. Chem Soc Rev 41(18), 5969 (2012).
39. Tang, X. et al. Paclitaxel-loaded nanoparticles of star-shaped cholic acid-core PLA-TPGS copolymer for breast cancer treatment. Nanoscale Res Lett 8(1), 420 (2013).
40. Zhang, J. et al. Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy. J Mater Sci Mater Med 26(4), 165 (2015).
41. Iyer, A. K., Khaled, G., Fang, J., Maeda, H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 11(17-18), 812 (2006).
42. Deng, X. et al. Photosan-II loaded hollow silica nanoparticles: preparation and its effect in killing for QBC939 cells. Photodiagnosis Photodyn Ther 10(4), 460 (2013).
43. Sabeti, B. et al. Development and characterization of liposomal doxorubicin hydrochloride with palm oil. Biomed Res Int 2014, 765426 (2014).
44. Hami, Z. et al. Doxorubicin-conjugated PLA-PEG-Folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation. Daru 22, 30 (2014).
45. Craparo, E. F. et al. Phospholipid-polyaspartamide micelles for pulmonary delivery of corticosteroids. Int J Pharm 406(1-2), 135 (2011).
46. Liu, C. et al. Folate-decorated and reduction-sensitive micelles assembled from amphiphilic polymer-camptothecin conjugates for intracellular drug delivery. Mol Pharm 11(11), 4258 (2014).
47. Peek, L. J., Roberts, L., Berkland, C. Poly(D,L-lactide-co-glycolide) nanoparticle agglomerates as carriers in dry powder aerosol formulation of proteins. Langmuir 24(17), 9775 (2008).
48. Lalatsa, A. et al. Amphiphilic poly(L-amino acids)-new materials for drug delivery. J Control Release 161(2), 523 (2012).
49. Swami, A. et al. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci USA 111(28), 10287 (2014).
50. Clementi, C. et al. Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms. Mol Pharm 8(4), 1063 (2011).
51. Xiao, K. et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32(13), 3435 (2011).
52. Kastantin, M. et al. Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin. J Phys Chem B 114(39), 12632 (2010).
53. Wu, H., Yao, L., Mei, J., Li, F. Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Pathol 8(1), 207 (2015).
54. Han, H. S. et al. Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy. J Control Release 200, 158 (2015).
55. Gillies, E. R., Frechet, J. M. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 16(2), 361 (2005).
56. Ozcan, I. et al. Synthesis and characterization of surface-modified PBLG nanoparticles for bone targeting: in vitro and in vivo evaluations. J Pharm Sci 100(11), 4877 (2011).
57. Wartenberg, M. et al. Doxorubicin distribution in multicellular prostate cancer spheroids evaluated by confocal laser scanning microscopy and the "optical probe technique". Cytometry 31(2), 137 (1998).
58. Liu, J. et al. Hyperbranched polyphosphates for drug delivery application: design, synthesis, and in vitro evaluation. Biomacromolecules 11(6), 1564 (2010).
59. Li, Q., Liu, C. G., Yu, Y. Separation of monodisperse alginate nanoparticles and effect of particle size on transport of vitamin E. Carbohydr Polym 124, 274 (2015).
60. Duan, X., Li, Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 9(9-10), 1521 (2013).
61. Langston, Suen WL & Chau, Y. Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells. J Pharm Pharmacol 66(4), 564 (2014).
62. Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5(4), 487 (2008).
63. Kulkarni, S. A., Feng, S. S. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 30(10), 2512 (2013).
64. Ju, C. et al. Sequential intra-intercellular nanoparticle delivery system for deep tumor penetration. Angew Chem Int Ed Engl 53(24), 6253 (2014).
65. Zong, T. et al. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm 11(7), 2346 (2014).
66. Wang, F. et al. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J Control Release 196, 222 (2014).